Evaluation and management of subclinical thyroid dysfunction

South African Medical Journal

Volumn 87, Issue 3 SUPPL., 1997, Pages 380-383

  Soule, S G ^a  

^a UNIVERSITY OF CAPE TOWN   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; HUMAN; HYPOTHYROIDISM; PATHOPHYSIOLOGY; RISK FACTOR;

HUMANS; HYPOTHYROIDISM; RISK FACTORS;

EID: 0031091181     PISSN: 02569574     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (17)

1. Elte JWF, Mudde AH, Kruseman ACN. Subclinical thyroid disease. Postgrad Med J 1996; 72: 141-146.
2. Jayme JJ, Ladenson PW. Subclinical thyroid dysfunction in the elderly. Trends Endocrinol Metab 1994; 5: 79-86.
3. Parle JV, Franklyn JA, Cross KW, Jones SC, Sheppard MC. Prevalence and follow-up of abnormal TSH concentrations in the elderly in the United Kingdom. Clin Endocrinol 1991; 34: 77-83.
4. Rosenthal MJ, Hunt WC, Garry PJ, Goodwin JS. Thyroid failure in the elderly: microsomal antibodies as discriminant for therapy. JAMA 1987; 256: 209-213.
5. Cooper DS, Halpern R, Wood LC, Levin AA, Ridgeway EC. L-thyroxine therapy in subclinical hypothyroidism. Ann Intern Med 1984; 101: 18-24.
6. Nystrom E, Caidahl K, Fager G. A double blind cross over 12 month study of L-thyroxine treatment of women with subclinical hypothyroidism. Clin Endocrinol 1988; 29: 63-76.
7. Haggerty JJ, Stern RA, Mason GA, Beckwith J, Morey CE, Prange AJ. Subclinical hypothyroidism: a modifiable risk factor for depression? Am J Psychiatry 1993; 150: 508-510.
8. Franklyn J. Subclinical hypothyroidism: to treat or not to treat, that is the question. Clin Endocrinol 1995; 43: 443-444.
9. Kung AWC, Pang RWC, Janus ED. Elevated serum lipoprotein(a) in subclinical hypothyroidism. Clin Endocrinol 1995; 43: 445-449.
10. Franklyn JA, Daykin J, Betteridge J, et al. Thyroxine replacement therapy and circulating lipid concentrations. Clin Endocrinol 1993; 38: 453-459.
11. Doctor R, Krenning EP, de Jong M, Henneman G. The sick euthyroid syndrome. Clin Endocrinol 1993; 399: 499-518.
12. Franklyn JA, Sheppard MC. The thyroid and osteoporosis. Trends Endocrinol Metab 1992; 3: 113-116.
13. Faber J, Galloe AM. Changes In bone mass during prolonged subclinical hyperthyroidism due to L-thyroxine treatment: a meta-analysis. Eur J Endocrinol 1994; 130: 350-356.
14. Leese GP, Jung RT, Guthrie C, Waugh N, Browning CK. Morbidity in patients on L-thyroxine: a comparison of those with a normal TSH to those with a suppressed TSH. Clin Endocrinol 1992; 37: 500-503.
15. Kung AWC, Yeung SSC. Prevention of bone loss induced by thyroxine suppressive therapy in postmenopausal women: the effect of calcium and calcitonin. J Clin Endocrinol Metab 1996; 81: 1232-1236.
16. Franklyn J, Betteridge J, Holder R, Daykin J, Lilley J, Sheppard J. Bone mineral density in thyroxine treated females with or without a previous history of thyrotoxicosis. Clin Endocrinol 1994; 41: 425-432.
17. Toft AD. Thyroxine therapy. N Engl J Med 1994; 331: 174-180.